Clinical Trial Update: Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of erlotinib and docetaxel in patients with Stage IV or recurrent breast cancer; results were posted in March 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Tarceva (erlotinib)
• Taxotere (docetaxel)

Snippet

Sponsor: Paula Silverman, MD | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2012-03-13